TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T.
Nature
554 :
2018
544-548
2659
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8<sup>+</sup> T cell tumor-infiltration impairing anti-PD1 therapy.
Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J.
Nat Commun
10 :
2019
2416
106
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Litchfield K, Reading JL, Lim EL, Xu H, Liu P, Al-Bakir M, Wong YNS, Rowan A, Funt SA, Merghoub T, Perkins D, Lauss M, Svane IM, Jönsson G, Herrero J, Larkin J, Quezada SA, Hellmann MD, Turajlic S, Swanton C.
Nat Commun
11 :
2020
3800
55
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Ahn SG, Kim SK, Shepherd JH, Cha YJ, Bae SJ, Kim C, Jeong J, Perou CM.
Breast Cancer Res Treat
188 :
2021
165-178
11
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P, Kadel Iii EE, Madireddi S, Au-Yeung A, Takahashi C, Chen YJ, Modrusan Z, McBride J, Nersesian R, El-Gabry EA, Robida MD, Hung JC, Kowanetz M, Zou W, McCleland M, Caplazi P, Eshgi ST, Koeppen H, Hegde PS, Mellman I, Mathews WR, Powles T, Mariathasan S, Grogan J, O'Gorman WE.
J Immunother Cancer
9 :
2021
e002231
65
Transcriptomic signatures of tumors undergoing T cell attack.
Gokuldass A, Schina A, Lauss M, Harbst K, Chamberlain CA, Draghi A, Westergaard MCW, Nielsen M, Papp K, Sztupinszki Z, Csabai I, Svane IM, Szallasi Z, Jönsson G, Donia M.
Cancer Immunol Immunother
71 :
2022
553-563
5
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.
McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY.
Sci Transl Med
13 :
2021
eabe6201
19
<i>ACSL4</i> Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer.
Luo W, Wang J, Dai X, Zhang H, Qu Y, Xiao W, Ye D, Zhu Y.
Front Oncol
11 :
2021
754845
5
Accounting for B-cell Behavior and Sampling Bias Predicts Anti-PD-L1 Response in Bladder Cancer.
Dyugay IA, Lukyanov DK, Turchaninova MA, Serebrovskaya EO, Bryushkova EA, Zaretsky AR, Khalmurzaev O, Matveev VB, Shugay M, Shelyakin PV, Chudakov DM.
Cancer Immunol Res
10 :
2022
343-353
6
Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification.
Chen Y, You S, Li J, Zhang Y, Kokaraki G, Epstein E, Carlson J, Huang WK, Haglund F.
Front Immunol
12 :
2021
788959
7
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.
Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, Furuya H, Trepel J, Di Vizio D, Guarnerio J, Theodorescu D, Rosser C, Apolo A, Galsky M, Chan KS.
Nat Commun
13 :
2022
1487
15
Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.
Lee HJ, Song KH, Oh SJ, Kim S, Cho E, Kim J, Park YG, Lee KM, Yee C, Song SH, Chang S, Choi J, Jung ST, Kim TW.
Nat Commun
13 :
2022
2127
5
Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer.
Zhang Q, Tan Y, Zhang J, Shi Y, Qi J, Zou D, Ci W.
Front Immunol
13 :
2022
782982
20
Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision Oncology.
Cho H, Tong F, You S, Jung S, Kim WH, Kim J.
IEEE Open J Eng Med Biol
3 :
2022
47-57
1
Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review.
Kovács SA, Győrffy B.
J Transl Med
20 :
2022
249
33
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, Tadros J, Ferretti AP, Liao S, Gurer C, Chen YH, Criscitiello S, Ricker CA, Dionne D, Rozenblatt-Rosen O, Uppaluri R, Haddad RI, Ashenberg O, Regev A, Van Allen EM, MacBeath G, Schoenfeld JD, Wucherpfennig KW.
Cell
185 :
2022
2918-2935.e29
117
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.
Seitz RS, Hurwitz ME, Nielsen TJ, Bailey DB, Varga MG, Ring BZ, Metts CF, Schweitzer BL, McGregor K, Ross DT.
J Transl Med
20 :
2022
370
3
Lactate: A regulator of immune microenvironment and a clinical prognosis indicator in colorectal cancer.
Zhu D, Jiang Y, Cao H, Yang J, Shu Y, Feng H, Yang X, Sun X, Shao M.
Front Immunol
13 :
2022
876195
13
Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy.
Subramanian M, Kabir AU, Barisas D, Krchma K, Choi K.
Cell Rep Med
4 :
2023
100896
12
M7G-related molecular subtypes can predict the prognosis and correlate with immunotherapy and chemotherapy responses in bladder cancer patients.
Li DX, Feng DC, Wang XM, Wu RC, Zhu WZ, Chen K, Han P.
Eur J Med Res
28 :
2023
55
12
The ratio of adaptive to innate immune cells differs between genders and associates with improved prognosis and response to immunotherapy.
Ahrenfeldt J, Christensen DS, Østergaard AB, Kisistók J, Sokač M, Birkbak NJ.
PLoS One
18 :
2023
e0281375
3
Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells.
Qin G, Liu S, Liu J, Hu H, Yang L, Zhao Q, Li C, Zhang B, Zhang Y.
Signal Transduct Target Ther
8 :
2023
164
7
The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response.
Dunker W, Zaver SA, Pineda JMB, Howard CJ, Bradley RK, Woodward JJ.
JCI Insight
8 :
2023
e167270
2
In situ tumour arrays reveal early environmental control of cancer immunity.
Ortiz-Muñoz G, Brown M, Carbone CB, Pechuan-Jorge X, Rouilly V, Lindberg H, Ritter AT, Raghupathi G, Sun Q, Nicotra T, Mantri SR, Yang A, Doerr J, Nagarkar D, Darmanis S, Haley B, Mariathasan S, Wang Y, Gomez-Roca C, de Andrea CE, Spigel D, Wu T, Delamarre L, Schöneberg J, Modrusan Z, Price R, Turley SJ, Mellman I, Moussion C.
Nature
618 :
2023
827-833
9
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
Ferreiro-Pantín M, Anido-Herranz U, Betancor YZ, Cebey-López V, León-Mateos L, García-González J, García-Acuña SM, Fernández-Díaz N, Tubio JMC, López-López R, Ruiz-Bañobre J.
ESMO Open
8 :
2023
101611
3
Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors.
Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, Shyer JA, Zhang Z, Mittman S, Gutierrez A, Astarita JL, Thai M, Hung J, Yang YA, Pourmohamad T, Himmels P, De Simone M, Elstrott J, Capietto AH, Cubas R, Modrusan Z, Sandoval W, Ziai J, Gould SE, Fu W, Wang Y, Koerber JT, Sanjabi S, Mellman I, Turley SJ, Müller S.
Nat Commun
14 :
2023
4703
11
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.
Schina A, Sztupinszki Z, Marie Svane I, Szallasi Z, Jönsson G, Donia M.
J Immunother Cancer
11 :
2023
e006941
3
Spatial transformation of multi-omics data unlocks novel insights into cancer biology.
Sokač M, Kjær A, Dyrskjøt L, Haibe-Kains B, Jwl Aerts H, Birkbak NJ.
Elife
12 :
2023
RP87133
1
Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer.
Yu QX, Wang JC, Liu JF, Ye LX, Guo YQ, Zheng HH.
Sci Rep
13 :
2023
14803
4
Integrating Single-Cell RNA-Seq and Bulk RNA-Seq Data to Explore the Key Role of Fatty Acid Metabolism in Breast Cancer.
Chen Y, Wu W, Jin C, Cui J, Diao Y, Wang R, Xu R, Yao Z, Li X.
Int J Mol Sci
24 :
2023
13209
0
Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy.
Zhao J, Dong Y, Bai H, Bai F, Yan X, Duan J, Wan R, Xu J, Fei K, Wang J, Wang Z.
Cell Rep Methods
3 :
2023
100596
3
Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer.
Kim K, Kim H, Shin I, Noh SJ, Kim JY, Suh KJ, Kim YN, Lee JY, Cho DY, Kim SH, Kim JH, Lee SH, Choi JK.
Sci Rep
13 :
2023
22482
1
Interferon-stimulated neutrophils as a predictor of immunotherapy response.
Benguigui M, Cooper TJ, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova A, Raviv Z, Buxbaum C, Christopoulos P, Bar J, Lotem M, Sznol M, Ariel A, Shen-Orr SS, Shaked Y.
Cancer Cell
42 :
2024
253-265.e12
11
T proliferating cells derived autophagy signature associated with prognosis and immunotherapy resistance in a pan-cancer analysis.
Fan Z, Liu Y, Li C, Jiang Y, Wang N, Wang M, Li C, Diao Y, Qiu W, Zhu X, Wang G, Cai S, Yang T, Lv G.
iScience
27 :
2024
108701
2
A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
Baek SW, Leem SH.
Int J Mol Sci
25 :
2024
3800
0
An endothelial-related prognostic index for bladder cancer patients.
Li DX, Wu RC, Wang J, Yu QX, Tuo ZT, Ye LX, Feng DC, Deng S.
Discov Oncol
15 :
2024
128
1
DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers.
Pineda JMB, Bradley RK.
Elife
12 :
2024
RP89017
3
Comprehensive pan-cancer analysis of mitochondrial outer membrane permeabilisation activity reveals positive immunomodulation and assists in identifying potential therapeutic targets for immunotherapy resistance.
Chen Q, Gao F, Wu J, Zhang K, Du T, Chen Y, Cai R, Zhao D, Deng R, Tang J.
Clin Transl Med
14 :
2024
e1735
0
MOSBY enables multi-omic inference and spatial biomarker discovery from whole slide images.
Şenbabaoğlu Y, Prabhakar V, Khormali A, Eastham J, Liu E, Warner E, Nabet B, Srivastava M, Ballinger M, Liu K.
Sci Rep
14 :
2024
18271
0
Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion.
Lapuente-Santana Ó, Sturm G, Kant J, Ausserhofer M, Zackl C, Zopoglou M, McGranahan N, Rieder D, Trajanoski Z, da Cunha Carvalho de Miranda NF, Eduati F, Finotello F.
iScience
27 :
2024
110529
0
Unveiling the pan-cancer landscape of S100A16: A comprehensive analysis of prognostic significance, drug sensitivity, and immunomodulatory roles.
Shang S, Hu L, Wu C, Wu J, Chen M, Zhu G, Xu WY, Zhang Y, Sun G, Wei Z.
Medicine (Baltimore)
103 :
2024
e39998
0